No awareness stage, because there is no unfamiliar audience left to reach.
Rare disease site design surfaces the specific clinical or trial information a specialist visitor came for immediately, skipping the generic top-of-funnel layout most pharma templates default to.
A small, expert audience arrives already informed and does not need persuasion content — the design surfaces the specific clinical or trial information it came for immediately, without a generic top-of-funnel layout in the way.
Search volume for a rare condition might be a few hundred queries a month worldwide, which makes broad-reach tactics pointless and precision the only strategy that works. Getting the design right starts from that fact, not from a moodboard.
An architecture with no generic awareness stage, a component system that surfaces specialist-relevant information immediately, and a review of where current content assumes an unfamiliar visitor that does not exist here.
A small, expert audience does not need persuasion content — it needs the specific clinical or trial information it came for surfaced immediately, without a generic awareness-stage layout in the way.
A significant share of rare disease traffic is a parent or patient reading after a difficult appointment, or during the long stretch before anyone has named the condition. That reader is anxious, often exhausted, and frequently on a phone. Design decisions that pass unnoticed elsewhere matter here: genuinely readable type, plain language ahead of clinical terminology, an honest route to what is and is not known, and no navigational dead ends. It also means resisting the pattern of pushing every path towards a product, because a reader who has not yet been diagnosed cannot use one and will not forgive being sold to.
In rare disease, advocacy groups and specialist centres carry more reach and considerably more trust than any manufacturer’s own channel. A site built to be useful to them — with material that can be referenced and linked without appearing promotional, clear terms for reuse, and accurate diagnostic and pathway information — becomes something those organisations point to. A site built purely as a brand presence gets ignored by exactly the network that could have carried it. The design consequence is a clear separation between genuinely educational material and product material, visible to a reader at a glance.
What comes up when scoping a site for this category.
Typically a small, specific population of specialists and patients, arriving with intent close to “rare disease specialist diagnosis” rather than a general health query. Search volume for a condition like this might be a few hundred queries a month worldwide, so the visitor who does arrive is usually further along in their own research than a typical health-topic visitor would be.
Content should be written for the small number of specialists and patients who will search for this exact condition, rather than broadened to capture unrelated traffic. Precise terminology, specific diagnostic criteria, and named specialists carry more value here than volume-driven keyword strategies built for larger categories. Broad-reach tactics are pointless at this search volume, and precision is the only strategy that returns anything.
Yes — that includes specialist-directory tools, patient-community features, and content reviewed for the precise diagnostic language this audience searches for. See Rare Disease for the full range of platforms and content we build for this sector, most of it built around a very small, very specific readership.
Where appropriate and requested, yes — a moderated community or resource-sharing element is sometimes valuable in a category with so few other patients to talk to. Moderation matters more here than in a general health community, since medical misinformation spreads easily within a small group that has limited outside information available to check it against.
By keeping disease education and product information structurally separate and letting the reader see which is which. Material about the condition, its symptoms, the diagnostic pathway and the organisations that support families can be genuinely useful and carries a much lighter review burden when it makes no product claim and names no product. The line is easiest to hold when it is designed in rather than edited out, which is why it is worth settling before anything is written.
A design that photographs well and still loses a small, specific population of specialists and patients halfway through the page. Tell us what you have tried and we will tell you what we think is actually going on. Tell us your situation and we will tell you what a rebuild for a small, specific population of specialists and patients would actually change.